These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 26100697)

  • 1. Prolonged entecavir therapy is not effective for HBeAg seroconversion in treatment-naive chronic hepatitis B patients with a partial virological response.
    Lee HW; Kwon JC; Oh IS; Chang HY; Cha YJ; Choi IS; Kim HJ
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5348-56. PubMed ID: 26100697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir.
    Choi HN; Song JE; Lee HC; Jo HH; Lee CH; Kim BS
    Clin Mol Hepatol; 2015 Mar; 21(1):24-31. PubMed ID: 25834799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum hepatitis B virus RNA is a predictor of HBeAg seroconversion and virological response with entecavir treatment in chronic hepatitis B patients.
    Luo H; Zhang XX; Cao LH; Tan N; Kang Q; Xi HL; Yu M; Xu XY
    World J Gastroenterol; 2019 Feb; 25(6):719-728. PubMed ID: 30783375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
    Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
    World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Partial virological response to entecavir treatment in nucleos(t)ide-naïve patients with HBeAg-positive chronic hepatitis B is not caused by reduced sensitivity.
    Li X; Li F; Zhang Y; Kang Y; Yu J; Yang F; Liu H; Qin Y; Huang Y; Mao R; Zhang J
    Biochem Biophys Res Commun; 2015 Sep; 464(4):1185-1191. PubMed ID: 26212437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Real-world Entecavir Therapy in Treatment-naïve Chronic Hepatitis B Patients.
    Xie YD; Ma H; Feng B; Wei L
    Chin Med J (Engl); 2017 Sep; 130(18):2190-2197. PubMed ID: 28875955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients.
    Ono A; Suzuki F; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Suzuki Y; Saitou S; Arase Y; Ikeda K; Kobayashi M; Watahiki S; Mineta R; Kumada H
    J Hepatol; 2012 Sep; 57(3):508-14. PubMed ID: 22659518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and virological outcomes of entecavir therapy in patients with chronic hepatitis B: A real life experience.
    Aljumah AA; Bin Selayem NA; Al-Howti SY; Dafallah M; AlGhamdi H; Mokhtar H; Albekairy AM; Sanai FM
    J Infect Chemother; 2019 Jan; 25(1):12-16. PubMed ID: 30366861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Durability of Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir.
    Fong TL; Tien A; Jo KJ; Chu D; Cheung E; Mena EA; Phan QQ; Yu AS; Mohammed W; Velasco A; LeDuc VH; Nguyen N; Han SB; Chang M; Bae HS; Cho YW; Tong MJ; Cooper SL
    Dig Dis Sci; 2015 Nov; 60(11):3465-72. PubMed ID: 26138653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety.
    Yuen MF; Seto WK; Fung J; Wong DK; Yuen JC; Lai CL
    Am J Gastroenterol; 2011 Jul; 106(7):1264-71. PubMed ID: 21364549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir.
    Pan CQ; Hu KQ; Yu AS; Chen W; Bunchorntavakul C; Reddy KR
    J Viral Hepat; 2012 Mar; 19(3):213-9. PubMed ID: 22329376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term virological outcome in chronic hepatitis B patients with a partial virological response to entecavir.
    Jo YJ; Kim KA; Lee JS; Kim NH; Bae WK; Song TJ; Kim JW
    Korean J Intern Med; 2015 Mar; 30(2):170-6. PubMed ID: 25750558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term impact of entecavir monotherapy in chronic hepatitis B patients with a partial virologic response to entecavir therapy.
    Ko SY; Choe WH; Kwon SY; Kim JH; Seo JW; Kim KH; Lee CH
    Scand J Gastroenterol; 2012 Nov; 47(11):1362-7. PubMed ID: 22934534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patients.
    Qiu YW; Huang LH; Yang WL; Wang Z; Zhang B; Li YG; Su TT; Zhou HY; Xu W; Wang XD; Dai YP; Gan JH
    Int J Infect Dis; 2016 Feb; 43():43-48. PubMed ID: 26523639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rescue monotherapy in lamivudine-resistant hepatitis B e antigen-positive chronic hepatitis B: adefovir versus entecavir.
    Lee JM; Kim HJ; Park JY; Lee CK; Kim DY; Kim JK; Lee HW; Paik YH; Lee KS; Han KH; Chon CY; Hong SP; Nguyen T; Ahn SH
    Antivir Ther; 2009; 14(5):705-12. PubMed ID: 19704174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Serum IFN- and IL-5 Levels in Response to Entecavir Therapy in Patients with Chronic Hepatitis B Virus Infection.
    Badary TM; ElBadawy O; Agban MN; Kamel S; Sadek A
    Egypt J Immunol; 2018 Jan; 25(1):93-103. PubMed ID: 30243001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years.
    Wong GL; Wong VW; Chan HY; Tse PC; Wong J; Chim AM; Yiu KK; Chu SH; Chan HL
    Aliment Pharmacol Ther; 2012 Jun; 35(11):1326-35. PubMed ID: 22506552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of entecavir treatment for up to 5 years in nucleos(t)ide-naïve chronic hepatitis B patients in real life.
    Luo J; Li X; Wu Y; Lin G; Pang Y; Zhang X; Ao Y; Du Z; Zhao Z; Chong Y
    Int J Med Sci; 2013; 10(4):427-33. PubMed ID: 23471472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On-treatment HBV DNA dynamics predict virological breakthrough in entecavir-treated HBeAg-positive chronic hepatitis B.
    Huang YJ; Chang CS; Peng YC; Yeh HZ; Yang SS
    PLoS One; 2017; 12(3):e0174046. PubMed ID: 28350873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.
    Chang TT; Lai CL; Kew Yoon S; Lee SS; Coelho HS; Carrilho FJ; Poordad F; Halota W; Horsmans Y; Tsai N; Zhang H; Tenney DJ; Tamez R; Iloeje U
    Hepatology; 2010 Feb; 51(2):422-30. PubMed ID: 20049753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.